Die Grafik zeigt die prognostizierten Quartalsgewinne (Bereinigter Gewinn pro Aktie, EPS) und die tatsächlich erzielten Gewinne (grün: Analystenschätzungen übertroffen, rot: Analystenschätzungen verfehlt) für den ausgewählten Zeitraum.
Umsatz (USD)
Schätzung
Umsatz
Die Grafik zeigt die prognostizierten Quartalsumsätze und die tatsächlich erzielten Umsätze (grün: Analystenschätzungen übertroffen, rot: Analystenschätzungen verfehlt) für den ausgewählten Zeitraum.
Güte der Analystenschätzungen – EPS (aktueller Zeitraum)
Quartal / Datum
EPS (USD)
Schätzung (USD)
Abweichung
Quartal / Datum
Umsatz (Mio USD)
Schätzung (Mio USD)
Abweichung
Revisionen der Gewinnschätzungen
EPS-Schätzungen für die Geschäftsjahre
2026, 2027, 2028.
Incyte secures EC approval for Povofortay, the first once-daily oral HS treatment in the EU, opening a new growth opportunity backed by strong clinical results.
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Povofortay® (povorcitinib) Approved in Europe as the First Once-Daily Oral Treatment for Adults with Moderate to Severe Hidradenitis Suppurativa.
Eurizon Capital SGR S.p.A. decreased its position in Incyte Corporation (NASDAQ: INCY) by 13.0% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 178,265 shares of the biopharmaceutical company's stock after selling 26,520 shares during the quarter. Eurizon Capital SGR S.p.A. owned
Incyte NASDAQ: INCY is preparing for a transition away from its JAKAFI business, with Chief Executive Officer Bill Meury pointing to product launches and a pipeline of late-stage drug candidates as potential sources of growth after 2029.
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (Nasdaq:NTRA), a global leader in cell-free DNA and precision medicine, today announced that it has entered into a clinical collaboration agreement with Incyte (Nasdaq:INCY) for a new phase II study in colorectal cancer (CRC). The trial will evaluate INCA33890, Incyte's investigational bispecific immunotherapy, in patients with stage 2/3 CRC who have completed surgery and adjuvant chemotherapy (ACT), incorporating Signatera as both a primary and seco.
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte is proud to announce that the University of Maryland School of Medicine and H. Lee Moffitt Cancer Center & Research Institute have been selected as the recipients of the 2026 Incyte Ingenuity Awards in GVHD™. This annual award program recognizes and supports innovative projects that address the specific needs of individuals impacted by graft-versus-host disease (GVHD), including patients, caregivers and healthcare providers. “It is our honor to reco.
Portfolios
0
Zum Anlegen oder Bearbeiten von Portfolios müssen Sie sich anmelden oder einen Account erstellen.
Aktuelle Aktie in ein Portfolio speichern oder neues Portfolio anlegen: